Ouabain downregulates Mcl-1 and sensitizes lung cancer cells to TRAIL-induced apoptosis

American Journal of Physiology - Cell Physiology

Volumn 304, Issue 3, 2013, Pages

  Chanvorachote, Pithi ^a   Pongrakhananon, Varisa ^a  

^a CHULALONGKORN UNIVERSITY   (Thailand)

Author keywords

Lung cancer; Mcl 1; Ouabain; TRAIL

Indexed keywords

CASPASE 3; FLICE INHIBITORY PROTEIN; HYDROGEN PEROXIDE; OUABAIN; POLY(ADENOSINE DIPHOSPHATE RIBOSE); PROTEIN BAX; PROTEIN BCL 2; PROTEIN MCL 1; REACTIVE OXYGEN METABOLITE; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND RECEPTOR;

APOPTOSIS; ARTICLE; CANCER CELL; CANCER GROWTH; CANCER RESISTANCE; CELL DEATH; CELL VIABILITY; CONTROLLED STUDY; DOWN REGULATION; ENZYME ACTIVATION; HUMAN; HUMAN CELL; HUMAN TISSUE; LUNG CANCER; PRIORITY JOURNAL; PROTEIN CLEAVAGE; PROTEIN DEGRADATION; PROTEIN FUNCTION; SENSITIZATION;

APOPTOSIS; CELL DEATH; CELL LINE, TUMOR; DOWN-REGULATION; DRUG SYNERGISM; HUMANS; HYDROGEN PEROXIDE; LUNG NEOPLASMS; OUABAIN; PROTEASOME ENDOPEPTIDASE COMPLEX; PROTO-ONCOGENE PROTEINS C-BCL-2; REACTIVE OXYGEN SPECIES; TNF-RELATED APOPTOSIS-INDUCING LIGAND; TRANSFECTION; UBIQUITIN;

EID: 84873371584     PISSN: 03636143     EISSN: 15221563     Source Type: Journal    
DOI: 10.1152/ajpcell.00225.2012     Document Type: Article

References (41)

1. Abdulghani J, El-Deiry WS. TRAIL receptor signaling and therapeutics. Expert Opin Ther Targets 14: 1091-1108, 2010.
2. Adams KW, Cooper GM. Rapid turnover of mcl-1 couples translation to cell survival and apoptosis. J Biol Chem 282: 6192-6200, 2007.
3. Anel A, Martinez-Lostao L. APO2L/TRAIL: new insights in the treatment of autoimmune disorders. Recent Pat Inflamm Allergy Drug Discov 5: 184-199, 2011.
4. Ark M, Ozdemir A, Polat B. Ouabain-induced apoptosis and Rho kinase: a novel caspase-2 cleavage site and fragment of Rock-2. Apoptosis 15:1494-506, 2010.
5. Blanco G, Mercer RW. Isozymes of the Na-K-ATPase: heterogeneity in structure, diversity in function. Am J Physiol Renal Physiol 275: F633- F650, 1998.
6. Blaustein MP. Endogenous ouabain: role in the pathogenesis of hypertension. Kidney Int 49: 1748-1753, 1996.
7. Day TW, Sinn AL, Huang S, Pollok KE, Sandusky GE, Safa AR. c-FLIP gene silencing eliminates tumor cells in breast cancer xenografts without affecting stromal cells. Anticancer Res 29: 3883-3886, 2009.
8. Falschlehner C, Emmerich CH, Gerlach B, Walczak H. TRAIL signalling: decisions between life and death. Int J Biochem Cell Biol 39: 1462-1475, 2007.
9. Gottlieb SS, Rogowski AC, Weinberg M, Krichten CM, Hamilton BP, Hamlyn JM. Elevated concentrations of endogenous ouabain in patients with congestive heart failure. Circulation 86: 420-425, 1992.
10. Han J, Goldstein LA, Gastman BR, Rabinowich H. Interrelated roles for Mcl-1 and BIM in regulation of TRAIL-mediated mitochondrial apoptosis. J Biol Chem 281: 10153-10163, 2006.
11. Huang YT, Chueh SC, Teng CM, Guh JH. Investigation of ouabain-induced anticancer effect in human androgen-independent prostate cancer PC-3 cells. Biochem Pharmacol 67: 727-733, 2004.
12. Kassouf N, Thornhill MH. Oral cancer cell lines can use multiple ligands, including Fas-L, TRAIL and TNF-alpha, to induce apoptosis in Jurkat T cells: possible mechanisms for immune escape by head and neck cancers. Oral Oncol 44: 672-682, 2008.
13. Kim SH, Ricci MS, El-Deiry WS. Mcl-1: a gateway to TRAIL sensiti-zation. Cancer Res 68: 2062-2064, 2008.
14. Kobayashi S, Werneburg NW, Bronk SF, Kaufmann SH, Gores GJ. Interleukin-6 contributes to Mcl-1 up-regulation and TRAIL resistance via an Akt-signaling pathway in cholangiocarcinoma cells. Gastroenterology 128: 2054-2065, 2005.
15. Kulikov A, Eva A, Kirch U, Boldyrev A, Scheiner-Bobis G. Ouabain activates signaling pathways associated with cell death in human neuro-blastoma. Biochim Biophys Acta 1768: 1691-1702, 2007.
16. Li Z, Xie Z. The Na/K-ATPase/Src complex and cardiotonic steroid-activated protein kinase cascades. Eur J Physiol 457: 635-644, 2009.
17. Lingrel JB. The physiological significance of the cardiotonic steroid/ ouabain-binding site of the Na,K-ATPase. Annu Rev Physiol 72: 395-412, 2010.
18. Malhi H, Gores GJ. TRAIL resistance results in cancer progression: a TRAIL to perdition? Oncogene 25: 7333-7335, 2006.
19. Manunta P, Ferrandi M, Bianchi G, Hamlyn JM. Endogenous ouabain in cardiovascular function and disease. J Hypertens 27: 9-18, 2009.
20. Nesher M, Dvela M, Igbokwe VU, Rosen H, Lichtstein D. Physiological roles of endogenous ouabain in normal rats. Am J Physiol Heart Circ Physiol 297: H2026-H2034, 2009.
21. Nicholls MG, Lewis LK, Yandle TG, Lord G, McKinnon W, Hilton PJ. Ouabain, a circulating hormone secreted by the adrenals, is pivotal in cardiovascular disease. Fact or fantasy? J Hypertens 27: 3-8, 2009.
22. Nijhawan D, Fang M, Traer E, Zhong Q, Gao W, Du F, Wang X. Elimination of Mcl-1 is required for the initiation of apoptosis following ultraviolet irradiation. Genes Dev 17: 1475-1486, 2003.
23. Ozdemir T, Nar R, Kilinc V, Alacam H, Salis O, Duzgun A, Gulten S, Bedir A. Ouabain targets the unfolded protein response for selective killing of HepG2 cells during glucose deprivation. Cancer Biother Radio-pharm 27: 457-463, 2012.
24. Sayers TJ. Targeting the extrinsic apoptosis signaling pathway for cancer therapy. Cancer Immunol Immunother 60: 1173-1180, 2011.
25. Schoner W, Scheiner-Bobis G. Endogenous and exogenous cardiac glycosides and their mechanisms of action. Am J Cardiovasc Drugs 7: 173-189, 2007.
26. Schoner W, Scheiner-Bobis G. Endogenous cardiac glycosides: hormones using the sodium pump as signal transducer. Semin Nephrol 25: 343-351, 2005.
27. Schoner W, Scheiner-Bobis G. Endogenous and exogenous cardiac glycosides: their roles in hypertension, salt metabolism, and cell growth. Am J Physiol Cell Physiol 293: C509-C536, 2007.
28. Schoner W. Endogenous cardiotonic steroids. Cell Mol Biol (Noisy-le-grand) 47: 273-280, 2001.
29. Selden R, Smith TW. Ouabain pharmacokinetics in dog and man. Determination by radioimmunoassay. Circulation 45: 1176-1182, 1972.
30. Taniai M, Grambihler A, Higuchi H, Werneburg N, Bronk SF, Farrugia DJ, Kaufmann SH, Gores GJ. Mcl-1 mediates tumor necrosis factor-related apoptosis-inducing ligand resistance in human cholangio-carcinoma cells. Cancer Res 64: 3517-3524, 2004.
31. +-ATPase is essential for ouabain's effect on [Ca2+] ion in rat cardiac myocytes. Am J Physiol Heart Circ Physiol 281: H1899-H1907, 2001.
32. Walther JU. Letter: ouabain in heart failure. Br Med J 1: 515, 1975.
33. Wang L, Chanvorachote P, Toledo D, Stehlik C, Mercer RR, Castra-nova V, Rojanasakul Y. Peroxide is a key mediator of Bcl-2 downregu-lation and apoptosis induction by cisplatin in human lung cancer cells. Mol Pharmacol 73: 119-127, 2008.
34. Wang X, Chen W, Zeng W, Bai L, Tesfaigzi Y, Belinsky SA, Lin Y. Akt-mediated eminent expression of c-FLIP and Mcl-1 confers acquired resistance to TRAIL-induced cytotoxicity to lung cancer cells. Mol Cancer Ther7: 1156-1163, 2008.
35. Winnicka K, Bielawski K, Bielawska A, Miltyk W. Apoptosis-mediated cytotoxicity of ouabain, digoxin and proscillaridin A in the estrogen independent MDA-MB-231 breast cancer cells. Arch Pharm Res 30: 1216-1224, 2007.
36. Yoshida T, Zhang Y, Rivera Rosado LA, Zhang B. Repeated treatment with subtoxic doses of TRAIL induces resistance to apoptosis through its death receptors in MDA-MB-231 breast cancer cells. Mol Cancer Res 7: 1835-1844, 2009.
37. Xie Z. Molecular mechanisms of Na/K-ATPase-mediated signal transduction. Ann NY Acad Sci 986: 497-503, 2003.
38. Zhang L, Fang B. Mechanisms of resistance to TRAIL-induced apoptosis in cancer. Cancer Gene Ther 12: 228-237, 2005.
39. Zhang Y, Zhang B. TRAIL resistance of breast cancer cells is associated with constitutive endocytosis of death receptors 4 and 5. Mol Cancer Res 6: 1861-1871, 2008.
40. Zitzmann K, de Toni E, von Rüden J, Brand S, Göke B, Laubender RP, Auernhammer CJ. The novel Raf inhibitor Raf265 decreases Bcl-2 levels and confers TRAIL-sensitivity to neuroendocrine tumour cells. Endocr Relat Cancer 18: 277-285, 2011.
41. Zong H, Yin B, Chen J, Ma B, Cai D, He X. Over-expression of c-FLIP confers the resistance to TRAIL-induced apoptosis on gallbladder carcinoma. Tohoku J Exp Med 217: 203-208, 2009.